Specific outcomes.
Real numbers.
Every story is a real engagement from the last twelve months — anonymized where clients require it, but never embellished.
Global Phase 3 monitoring team assembled in twenty-two days.
The call came on a Tuesday. A Series B biotech running a Phase 3 cardiovascular trial had a monitoring gap across fourteen countries. Their CRO could not deliver on the timeline. The in-house hiring path was a fantasy. The next milestone was nine weeks away and every day without coverage was a day of protocol drift, site risk, and program slip. By the end of the week Peritia had matched the first eight CRAs. By day fifteen, twenty were in place. By day twenty-two the full team of twenty-two specialists was deployed across all fourteen countries — onboarded, trained on the EDC, and actively monitoring. The trial hit its next milestone on schedule. None of that happened because of a staffing agency. All of it happened because the pre-vetted network had the right people on the bench, and the intake desk ran a live match queue until the team was complete.
More outcomes. On the record.
Phase 3 Ops Lead placed in 6 days.
Replacement with therapeutic area experience working inside the EDC by day five. Readout shipped on schedule.
BLA strategist inside agency in 72 hours.
Three ex-FDA strategists returned within the 48-hour window. Filing strategy locked in ten days.
HEOR team in three markets.
Three-market HEOR dossier team assembled in one week. Value story shaped for payers across NICE, G-BA, HAS.
Launch readiness lead scoped in 1 week.
Launch veteran with three prior directly relevant launches. Functional orchestration complete in six weeks.
Investor advisor placed pre-S1.
Senior advisor with two prior S1s added fourteen days before drafting began. Drafting cycle did not slip.
Interim CMO seated through approval.
Interim CMO seated in nine days. Stayed through BLA filing and approval. Nine month engagement.